Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30.

Analysts expect the Tarrytown, New York-based company to report quarterly earnings at $10.74 per share, down from $12.07 per share in the year-ago period. The consensus estimate for Regeneron Pharmaceuticals' quarterly revenue is $3.79 billion, versus $3.79 billion a year earlier, according to data from Benzinga Pro.

On Dec. 1, Regeneron Pharmaceuticals and Tessera Therapeutics, Inc., announced a global collaboration to develop and commercialize TSRA-196.

Regeneron Pharmaceuticals shares fell 0.2% to close at $749.44 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Considering buying REGN stock? Here’s what analysts think:

Photo via Shutterstock